AION sees positive intravascular contrast results for MI platform
AION Diagnostics, a nano-diagnostics company developing medical imaging agents, announced positive preliminary results of a pilot study showing the high intravascular contrast enhancement of modified porous silicon (mpSi) in reduced dose amounts.

The trialled intravascular contrast agent is based on the same formulation as AION's Marking Agent, a medical device to be registered under the CE Mark in Europe and via 510(K) approval in the U.S.

“These interim results provide an excellent advancement to consolidate AION's position in the ultrasound imaging sector. Ultrasound is a powerful imaging technique that can be used in a wide variety of settings, including surgical, outpatient, emergency room and community healthcare environments. Ultrasound avoids the need for expensive and radiation-emitting modalities, and provides clinicians with a practical solution for early detection of cardiovascular disease and cancer,” said Anna Kluczewska, MD, president and CEO.

mpSi is also visible under other key imaging modalities namely MRI, CT, x-ray and optical imaging.

The high visibility of mpSi at low dose is of importance in molecular imaging applications due to the necessity to image minute clusters of diseased cells.

In the in vivo study, a bolus injection of mpSi in saline suspension was administered intravenously. Ultrasonographic imaging of the vasculature and heart indicated that the mpSi showed high echogenicity and produced strong contrast enhancement with no change in vital signs or evidence of acute cardiovascular or respiratory adverse effects.